Home
 /
Papers
 /
Cancer Biology
 /
Tumor Genotype Dictates Mitochondrial and Immune Vulnerabilities in Liver Cancer
Preprint
Open access
V1
Top 1% · Validated by QED

Tumor Genotype Dictates Mitochondrial and Immune Vulnerabilities in Liver Cancer

Gokhan Unlu, Alon Millet, Khando Wangdu +22 more
September 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.09.10.675369
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cancer Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

This study overturns the notion of a uniform tumor metabolism by proving that oncogene identity programs distinct mitochondrial liabilities, and establishes PE synthesis as a direct mechanism linking lipid biology to tumor immune evasion.

QED claims analysis

Summary

Oncogene identity dictates distinct mitochondrial metabolic programs in primary liver cancer, creating genotype-specific vulnerabilities: Kras-driven tumors depend on creatine metabolism for energy buffering during early tumorigenesis, while PTEN-deficient c-MYC-driven tumors rely on phosphatidylethanolamine synthesis, which promotes immune evasion by suppressing TNF receptor-mediated cytotoxicity and CD8+ T cell infiltration.

See full analysis
Main Claim 1 –

Oncogene Identity Dictates Mitochondrial Metabolic Programming in Liver Cancer

Supporting evidence

  • Rapid Mitochondrial Immunopurification Enables Cell-Type-Specific Metabolic Profiling In Vivo
  • MYC-Driven Liver Tumors Depend on Oxidative Phosphorylation
Main Claim 2 –

Creatine Metabolism Is a Selective Vulnerability in KRAS-Driven Liver Cancer

Supporting evidence

  • KRAS Tumor Regions Accumulate Creatine and Phosphocreatine
  • Creatine Metabolism Inhibition Selectively Suppresses KRAS-Driven Tumor Growth
  • Creatine Metabolism Buffers Profound Energy Stress in KRAS Tumors
  • Creatine Metabolism Is Required Specifically During Early KRAS Tumorigenesis
  • High Creatine Metabolism Predicts Poor Survival in KRAS-Mutant ICC
Main Claim 3 –

PCYT2-Dependent PE Synthesis Sustains PTEN-Deficient MYC Liver Tumors

Supporting evidence

  • PTEN Loss Drives Enhanced Lipid Synthesis and Storage in PLC
  • Altering PE Availability Directly Modulates PTEN-Deficient Tumor Progression
Main Claim 4 –

PE Synthesis Inhibition Boosts Adaptive Anti-Tumor Immunity in PTEN-Null PLC

Supporting evidence

  • PE Synthesis Blockade Increases CD8+ T Cell Infiltration and Activation
  • PE Synthesis Inhibition Sensitizes Tumor Cells to T Cell Killing

Abstract

Although oncogenic alterations influence tumor metabolism, how they impose distinct metabolic programs within a shared tissue context remains poorly defined. Here, we developed a rapid mitochondrial profiling platform to compare metabolites and proteins in genetic models of primary liver cancer (PLC). Analyses of six genetically distinct PLCs revealed that mitochondrial energy metabolism is largely dictated by oncogene identity. Kras-driven tumors required creatine metabolism to buffer energy demands during early tumorigenesis, whereas c-MYC-driven tumors relied on oxidative phosphorylation. Among c-MYC-driven PLCs, Pten-deficient tumors accumulated mitochondrial phosphoethanolamine, a precursor for phosphatidylethanolamine (PE) synthesis. Inhibition of PE synthesis selectively impaired the growth of Pten-deficient tumors and extended survival, in part through enhanced infiltration of CD8⁺ T cells and sensitization to TNFα-mediated cytotoxicity. Mechanistically, loss of PE elevated surface TNF receptor 2 (TNFR2), promoting TNFα signaling and pro-inflammatory response. These findings uncover genotype-specific mitochondrial metabolic liabilities and establish PE synthesis as a tumor-intrinsic mechanism of immune evasion in PLC.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?